Glycourso<wbr/>deoxycholic Acid

Glycoursodeoxycholic Acid

CAT N°: 21698
Price:

From 48.00 40.80

Glycoursodeoxycholic acid (GUDCA) is a glycine-conjugated form of the secondary bile acid ursodeoxycholic acid (UDCA; Item No. 15121).{48223,34418} It has antioxidant effects in vitro in Barrett’s esophagus cells and primary cultured rat neurons.{34417,34415} GUDCA reduces the levels of inflammatory cytokines and prevents cell death induced by unconjugated bilirubin in an astroglial cell model of neonatal hyperbilirubinemia.{34416} Oral administration of GUDCA (500 mg/kg per day) decreases the severity of symptoms and increases the amount of A. muciniphila, a bacterial species commonly decreased in patients with inflammatory bowel disease (IBD), in a mouse model of colitis.{34418}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-[(3?,5?,7?)-3,7-dihydroxy-24-oxocholan-24-yl]-glycine
  • Correlated keywords
    • 474-26-0 2273-95-2 anti-oxidant ursodeoxycholylglycine glyclursodeoxycholic akkermansia GUD CA UD hyper-bilirubinemia
  • Product Overview:
    Glycoursodeoxycholic acid (GUDCA) is a glycine-conjugated form of the secondary bile acid ursodeoxycholic acid (UDCA; Item No. 15121).{48223,34418} It has antioxidant effects in vitro in Barrett’s esophagus cells and primary cultured rat neurons.{34417,34415} GUDCA reduces the levels of inflammatory cytokines and prevents cell death induced by unconjugated bilirubin in an astroglial cell model of neonatal hyperbilirubinemia.{34416} Oral administration of GUDCA (500 mg/kg per day) decreases the severity of symptoms and increases the amount of A. muciniphila, a bacterial species commonly decreased in patients with inflammatory bowel disease (IBD), in a mouse model of colitis.{34418}

We also advise you